January 12, 2022 -- PostEra has closed $24 million in equity financing to accelerate medicinal chemistry and bring new cures to patients. The company also announced a multitarget strategic partnership with Pfizer to establish an artificial intelligence lab.
The proceeds will go toward advancing a series of partnered drug discovery programs and further developing PostEra's medicinal chemistry platform.
Over the past 18 months, PostEra has proven its platform on a wide variety of drug discovery programs by tightly integrating the design-make-test cycle of medicinal chemistry, the company said. Recent results include the rapid development of COVID oral antiviral candidates via COVID Moonshot and the advancement of several drug discovery efforts with biopharma partners.
PostEra was founded in 2019. The Clermont Group led the series A financing with participation from Breyer Capital, Lifeforce Capital, I2BF Global Ventures, and existing investors Metaplanet, HOF Capital, Ace & Company, Pioneer Fund, and R. Martin Chavez.